Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896761 · ClinicalTrials.gov registry record · Phase 3
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
A Phase 3 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
NCT05896761 is a Phase 3 study that has completed, run by ViiV Healthcare. The registered enrollment target is 118 participants.
The verdict
NCT05896761, a Phase 3 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
Study Summary
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS2M \[A2M\]) study (NCT03299049).
Interventions
- DRUG Cabotegravir Injectable Suspension
- DRUG Rilpivirine Injectable Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05896761
The ClinicalTrials.gov registry entry for NCT05896761 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabotegravir Injectable Suspension is the first listed.
NCT05896761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05896761 about?
NCT05896761 is a clinical study titled "A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants". This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected adult participants currently enrolled in the Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLAS2M \[A2M...
What is the current status of trial NCT05896761?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2021-10-28. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT05896761?
The interventions under investigation include: Cabotegravir Injectable Suspension (DRUG), Rilpivirine Injectable Suspension (DRUG).
Who is sponsoring clinical trial NCT05896761?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.